GEN1047 for Solid Tumors - First in Human (FIH) Trial

Summary

The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: * The side effects seen with GEN1047 * What the body does with GEN1047 once it is administered * What GEN1047 does to the body once it is administered * How well GEN1047 works against solid tumors The estimated trial duration for an individual participant is 8 months, consisting of a 28-day screening period, an estimated 3 month treatment period (the duration of treatment may vary for each participant), and an estimated 4 month post-treatment follow-up period (the duration of follow-up may vary for each participant). All participants will receive active drug; no one will be given placebo.

Timeline

Start

2021-12-13

Primary completion

2026-03-25

Completion

2026-03-25

Outcome

Outcome not reported

Stopped (Business): “The Sponsor has made a strategic decision to stop the development of GEN1047.”

Drugs

Indications